What is the importance of difference in LCM strategy in drug development? – Learnings from Keytruda and Opdivo

Immune checkpoint inhibitors have changed how cancer is treated. As of February 2022, six immune checkpoint inhibitors had been approved, with Keytruda and Opdivo accounting for the majority of global sales. Here, the impact of the differences in commercial success between Keytruda and Opdivo is reviewed by analyzing inter-organizational deals since their launch in 2014. Both showed a correlation between the cumulative number of indications and product sales trends, the latter crossing from 2017 to 2018. Differences in sales were due to different approaches to life cycle management by inter-organizational deals and drug development strategies, the key to commercial success.